VH-IVUS Plaque Composition Analysis By Fractional Flow Reserve

Sponsor
Inje University (Other)
Overall Status
Completed
CT.gov ID
NCT01444599
Collaborator
Seoul National University Hospital (Other)
100
4
57
25
0.4

Study Details

Study Description

Brief Summary

Recent clinical trials demonstrated that virtual histology-intravascular ultrasound (VH-IVUS) is a useful test predicting clinical outcomes of the coronary artery disease (CAD). Thin cap fibroatheroma (VH-TCFA) was proposed a predictor of cardiovascular event by VH-IVUS combined with more than 70% plaque burden and less than 4mm² minimal lumen area (MLA) by IVUS. Fractional flow reserve (FFR) is an established index of the physiological significance of a coronary stenosis. Recent large scale trials demonstrated FFR guided PCI showed favorable clinical outcomes. VH-IVUS represents anatomical severity, but FFR represents functional severity of CAD. Few studies reported relevance between two tests. Aim of this study was to investigate whether the geometry and composition of lesions were different under FFR criteria.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    100 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Cross-Sectional
    Official Title:
    Virtual Histology (VH)-Intravascular Ultrasound (IVUS) Tissue Characteristics Analysis of the Intermediate Coronary Artery Stenosis Lesion Predicting Physiologic Myocardial Ischemia by Myocardial Fraction Flow Reserve (FFR)
    Study Start Date :
    Mar 1, 2010
    Actual Primary Completion Date :
    Aug 1, 2014
    Actual Study Completion Date :
    Dec 1, 2014

    Arms and Interventions

    Arm Intervention/Treatment
    low FFR group (<0.8)

    the patient with FFR values less than 0.8

    high FFR group (>0.8)

    the patient with FFR values greater than 0.8

    Outcome Measures

    Primary Outcome Measures

    1. Differences VH-IVUS plaque composition between different FFR groups [baseline]

      VH-IVUS tissue composition (necrotic core, dense calicium, fibrotic, fibrofatty %) and atheroma type will be compared according to different FFR groups at the time of measurement procedure.

    Secondary Outcome Measures

    1. Serial physiologic and plaque composition changes of deferred lesions at 1 year FFR and VH-IVUS follow-up. [one year]

      Approximately 60-70 of 100 enrolled patients would be deferred according to FFR values. Patient who provide consent for clinical and angiographic follow-up at one year would be assessed by physiologic FFR and VH-IVUS derived plaque composition. Relationship of serial physiologic and plaque composition changes will be evaluated. Anatomic and physiologic parameters associated with plaque progression and/or regression will be determined.

    2. Serial physiologic and plaque composition changes of stented lesions at 1 year FFR and VH-IVUS follow-up. [one year]

      Approximately 30-40 of 100 enrolled patients would be stented according to FFR values. Patient who provide consent for clinical and angiographic follow-up at one year would be assessed by physiologic FFR and VH-IVUS derived plaque composition including stented segment. Relationship of serial physiologic and plaque composition changes will be evaluated. Anatomic and physiologic parameters associated with stent failure will be determined.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • clinical angina pectoris who underwent VH-IVUS and FFR during coronary angiography.

    • agree with informed consent

    Exclusion Criteria:
    • unable to get informed consent

    • low left ventricular ejection fraction less than 35%

    • chronic renal failure (Cr>2.0mg/dl)

    • acute myocardial infarction related coronary artery

    • allergy to adenosine injection

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Inje University Ilsan Paik Hospital Goyang Gyeonggido Korea, Republic of 411-709
    2 Keimyung University Dongsan Medical Center Daegu Korea, Republic of
    3 Seoul National University Hospital Seoul Korea, Republic of
    4 Ulsan University Hospital Ulsan Korea, Republic of

    Sponsors and Collaborators

    • Inje University
    • Seoul National University Hospital

    Investigators

    • Principal Investigator: Joon Hyung Doh, MDPhD, Inje University Ilsan Paik Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Joon Hyung Doh, Associate Professor of Medicine, Inje University
    ClinicalTrials.gov Identifier:
    NCT01444599
    Other Study ID Numbers:
    • IB-1110-048
    First Posted:
    Oct 3, 2011
    Last Update Posted:
    Mar 24, 2015
    Last Verified:
    Mar 1, 2015
    Keywords provided by Joon Hyung Doh, Associate Professor of Medicine, Inje University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 24, 2015